Serum interferon beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients.
Neurology
; 51(3): 738-42, 1998 Sep.
Article
em En
| MEDLINE
| ID: mdl-9748019
ABSTRACT
BACKGROUND:
The pharmacokinetics of IFNbeta-1a in MS patients are poorly understood. We have previously reported an ELISA sensitive and specific for measuring serum IFNbeta-1b levels in patients with MS.OBJECTIVE:
We describe an ELISA to measure interferon beta-1a (Avonex) in the serum of MS patients following IM administration.METHODS:
We have developed an ELISA for detecting serum IFNbeta-1a in MS patients receiving 6 million units (MU) of IFNbeta-1a, IM once weekly. The specificity of this ELISA was confirmed by the lack of cross-reactivity with other cytokines except for IFNbeta-1b.RESULTS:
Serum IFNbeta-1a levels were measured at 3 and 6 months after initiating treatment with IFNbeta-1a in 10 MS patients. At 3 months, all 10 patients had detectable levels ranging from 68 to 86 IU/mL. At 6 months, IFNbeta-1a could be detected in the serum of all but three patients, with levels ranging from 64 to 81 IU/mL. A kinetic study of IFNbeta-1a serum levels in a separate group of six MS patients who had been receiving IFNbeta-1a for several months was carried out. Blood was drawn before and 2, 4, 6, 8, and 24 hours after IFNbeta-1a injection. Peak serum IFNbeta-1a levels were observed at 8 hours and became undetectable at 24 hours after injection.CONCLUSION:
The described ELISA may have useful clinical applications in examining the correlation between serum IFNbeta-1a levels and clinical efficacy.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ensaio de Imunoadsorção Enzimática
/
Interferon beta
/
Esclerose Múltipla
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
Idioma:
En
Revista:
Neurology
Ano de publicação:
1998
Tipo de documento:
Article
País de afiliação:
Estados Unidos